Full Press Release Details
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin.
IRON
Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
Key Takeaway: Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin
Price reaction · baseline $49.59 (2023-11-13 close) · hit after-hours · clean, no other IRON news in the window
day 0 close · peak
+4.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+45%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Cash runway
~48 mo
Minimal dilution risk
Lead asset
DISC-0974
Phase 2 · Inflammatory Bowel Disease (IBD)